

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



深圳市海王英特龍生物技術股份有限公司

SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8329)

**VOLUNTARY ANNOUNCEMENT
RECEIPT OF REGULATORY DECISION LETTER
BY THE CONTROLLING SHAREHOLDER**

The announcement is made by Shenzhen Neptunus Interlong Bio-technique Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company hereby informs that Shenzhen Neptunus Bio-engineering Company Limited (“**Neptunus Bio-engineering**”), the controlling shareholder of the Company, has received a decision letter from the Shenzhen Regulatory Bureau of China Securities Regulatory Commission (the “**CSRC Shenzhen Regulatory Bureau**”), in which the CSRC Shenzhen Regulatory Bureau decides to impose corrective regulatory measures against Neptunus Bio-engineering and its controlling shareholder. The decision letter states that Neptunus Bio-engineering shall take proactive measures to recover the misappropriated funds, so as to safeguard the interests of the listed company and its minority shareholders; and that its controlling shareholder shall effectively fulfill its primary responsibility and actively raise funds to repay the misappropriated funds. Neptunus Bio-engineering and its controlling shareholder should take the lessons seriously, intensify the study of securities laws and regulations, and prevent any recurrence of such violations. All misappropriated funds shall be returned within six months from the date of receipt of the said decision letter, and a written report shall be submitted to the CSRC Shenzhen Regulatory Bureau upon completion of the rectification.

For details, please refer to the evening announcement of Neptunus Bio-engineering dated 28 August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, the PRC, 31 August 2026

As at the date of this announcement, the executive Directors are Mr. Zhang Feng, Mr. Huang Jian Bo and Mr. Zhang Xiao Guang; the non-executive Directors are Mr. Zhang Yi Fei, Mr. Jin Rui and Mr. Zhang Xiao Peng; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Ms. Zhu Jia Min.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from its date of publication and on the Company’s website at www.interlong.com.

* For identification purpose only